RNAi Technology Market to Hit $5.5 Billion by 2034 as CAGR Nears 14%
Updated
Updated · Yahoo Finance · Aug 25
RNAi Technology Market to Hit $5.5 Billion by 2034 as CAGR Nears 14%
1 articles · Updated · Yahoo Finance · Aug 25
Summary
$5.5 billion is DelveInsight’s 2034 forecast for the global RNAi technology market, up from $1.6 billion in 2025.
About 14% annual growth is tied to more approvals and commercialization of RNAi therapies for rare genetic, metabolic, cardiovascular and liver diseases.
Lipid nanoparticles and GalNAc conjugates are improving RNAi drug delivery, safety and efficacy, helping speed clinical development.
North America is the largest regional market, while siRNA is the biggest molecule segment.
Rising biotech investment, more pharma-biotech partnerships and expanding use in precision medicine and oncology are expected to keep the market growing.
With AI accelerating RNAi discovery and market value soaring, could unresolved extrahepatic delivery hurdles suddenly crash this multi-billion-dollar biotech boom?
As RNAi therapies shift from IV to subcutaneous dosing, will the race for patient convenience ultimately crown shRNA as the new market dominator?